Liquidia Corporation (LQDA) 股票分析

公司概述

Liquidia Corporation operates as a biopharmaceutical entity focused on the development, manufacturing, and commercialization of products designed to treat rare cardiopulmonary diseases within the United States market. The company is situated in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry, which characterizes its operational environment and competitive landscape. With a market capitalization of $3.55B, the company reports trailing twelve-month revenue of $158.32M and employs a workforce of 216 individuals. These valuation and revenue figures indicate that Liquidia holds a significant position in the specialty pharmaceutical space, suggesting substantial market interest despite the challenges inherent in developing treatments for rare diseases.

财务健康

The company reported trailing twelve-month revenue of $158.32M alongside a net income of $-68,924,000 and an EBITDA of $-50,348,000, revealing a cost structure where operating expenses significantly outweigh earnings before interest and taxes. Free cash flow stands at $-43,121,500, indicating that the company is currently consuming cash rather than generating it, which limits immediate financial flexibility and relies on external capital sources or internal reserves. The gross margin is recorded at 91.6%, reflecting the high value added during the production phase of pharmaceutical goods, while the operating margin sits at 21.5%, showing that operational costs consume a notable portion of gross revenue. However, the profit margin is -43.5%, which underscores the substantial impact of non-operating expenses or significant research and development costs on the bottom line. In terms of liquidity and leverage, the company holds $190.68M in cash against $197.93M in debt, resulting in a debt-to-equity ratio of 442.31% that signifies a highly leveraged balance sheet. The current ratio of 2.01 suggests that the company possesses sufficient current assets to cover its short-term liabilities, maintaining a baseline of solvency despite the heavy debt load. Return on equity is -111.1% and return on assets is -11.5%, metrics that reveal management is currently utilizing shareholder capital and company assets to generate losses rather than positive returns.

估值评估

The trailing P/E ratio is listed as N/A due to negative earnings, whereas the forward P/E is 7.70, implying that the market anticipates a significant turnaround in earnings trajectory over the next fiscal period. The price-to-book ratio stands at 78.60, indicating a substantial market premium over the company's book value, likely driven by the potential value of its pipeline and intangible assets rather than current tangible net worth. Alternative valuation metrics show a price-to-sales ratio of 22.44 and an EV/EBITDA of -70.71, suggesting that traditional multiple-based comparisons are skewed by current losses and that valuation relies heavily on future revenue potential. The stock's 52-week trading range spans from a low of $11.26 to a high of $46.67, providing a context for the current price level relative to its recent volatility. The beta value of 0.46 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market fluctuations.

Growth & Income

Revenue growth year-over-year is reported at an exceptional 3054.6%, while earnings growth is N/A due to the absence of net income, implying that revenue expansion is not yet translating into profitability. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A and 0.0% respectively, indicating that earnings are not distributed to shareholders but are instead retained to fund operations and growth initiatives. The overall growth and income profile is defined by explosive top-line expansion coupled with a complete reinvestment of cash flows into the business to achieve future profitability. This profile suggests a high-risk, high-reward dynamic typical of early-stage pharmaceutical companies attempting to commercialize new therapeutic candidates.